Latigo Biotherapeutics, Inc.

#News: We're excited to announce that the first participant has been dosed in our Phase 1 clinical trial for LTG-305. This is our second program to enter the clinic and a further milestone in our mission to provide effective, non-addictive pain relief to millions of patients in need. Read our press release for full details: https://lnkd.in/gHJFupPx #LatigoBiotherapeutics #PainManagement #NonOpioidTherapy #BioPharma

September is #PainAwarenessMonth, which this week International Association for the Study of Pain focuses on scientific research and assessment. Latigo was founded on a deep commitment to relieving pain and restoring health to many millions of pain sufferers. Our goal remains clear: to develop a non-opioid pain medicine that targets pain at its source. As we continue to explore new avenues in research and development, it’s our privilege to stand with the community in recognizing this important month and #SolvePainTogether

We are excited to announce the appointment of Tim Lugo as our new Chief Financial Officer and the addition of Beth Seidenberg, M.D., and Jim Tananbaum, M.D., to our board of directors. Tim brings over two decades of experience in biotechnology finance and equity research, while Dr. Seidenberg and Dr. Tananbaum are seasoned venture capitalists. Their expertise will be instrumental as we scale and accelerate the development of our non-opioid pain medicines. Welcome to the Latigo Biotherapeutics, Inc. team! Click the link below to read the full press release. 👇 https://lnkd.in/gHJFupPx #NonOpioidPainRelief #Leadership #BioPharma

Today, we announced new Phase 1 data about the safety and tolerability of our therapeutic approach that may provide pain patients with an alternative to opioids. LTG-001 is an oral, selective Nav1.8 inhibitor in development to treat acute and chronic pain at its source. Opioid addiction is a national public health concern – 3.75 million Americans go on to long-term chronic opioid use after low-risk surgery as up to 19% of patients exposed to opioids develop dependency. We are also thrilled to welcome world-renowned analgesic scientist Neil Singla, MD as our chief medical officer. Learn more about these results and our commitment to provide effective, rapid-acting pain relief without the risk of addiction. https://lnkd.in/guXWFrrv #BioPharma #Biotechnology #Pharma #News #PainManagement #NonOpioid

Attending the International Association for the Study of Pain World Congress on Pain has left me even more inspired to revolutionize pain treatment and improve societal health. Chronic pain impacts a significant portion of the U.S. population, with one in five individuals experiencing it daily, surpassing the prevalence of diabetes, depression, and high blood pressure. Around 80 million Americans are prescribed medication for acute pain each year, with effects lasting less than three months. However, the issue of opioid misuse cannot be overlooked. In 2020, doctors wrote 143 million opioid prescriptions, and around 3.75 million Americans go on to long-term chronic opioid use after low-risk surgery. According to the American Medical Association, up to 19% of individuals who take prescription opioid medications develop an addiction to them. Disturbingly, the National Institute on Drug Abuse reports that over 80% of individuals who use illicit opioids started with prescription opioids. Addressing these challenges requires innovative solutions in pain therapeutics. There have been no novel chemical entities (NCEs) approved for chronic or acute pain in two decades, excluding drugs for migraines. I spoke with a doctor from Florida about his frustration with the therapeutic options for patients in pain today. He described currently approved drugs as “square pegs for round holes.” Regrettably, recent data shows a decline in the industry-wide clinical pipeline for NCE pain treatments. However, at Latigo Biotherapeutics, Inc., we are committed to bridging this gap. We firmly believe in harnessing life science innovation to redefine pain management and enhance societal health. Engaging with doctors, patients, and stakeholders at the congress reinforced their anticipation for effective non-opioid pain therapies. As the CEO of Latigo, I am immensely proud of our team and our dedication to transforming the pain treatment landscape and saving lives. Join us on this transformative journey in pain research and non-opioid medicine. Together, we can bring about real change and improve the lives of millions. Nima Pictured: our SVP Discovery Bryan Moyer presenting research into targeting the sodium channel NaV1.8. and its potential to block pain at its source. #WC2024 #PainResearch #NonOpioidMedicine 

From the International Association for the Study of Pain World Congress #WC2024 👇

This week, we are at the International Association for the Study of Pain World Congress on Pain (Amsterdam, August 5-9)   Our Senior Vice President, Discovery, Bryan Moyer, Ph.D., will be sharing our research into targeting the sodium channel NaV1.8. and potential to block pain at its source.   We hope you can join us in Amsterdam.   IASP Poster session #FR446 A Selective Small Molecule Inhibitor of NaV1.8 with a Unique Mechanism of Action August 9, 2024, 9:30 to 11:00 am Presenting author: Bryan Moyer, Ph.D., Latigo Biotherapeutics   https://lnkd.in/gJB5dZsT   #PainManagement #IASPCongress #IASP2024

We are thrilled to announce the appointment of Nima Farzan, MBA., as our Chief Executive Officer of Latigo Biotherapeutics.   Most recently CEO of therapeutic companies Kinnate Biopharma (acquired by XOMA corporation) and PaxVax Corporation (acquired by Emergent BioSolutions), Nima said: "I am honored to lead Latigo Biotherapeutics at such a critical juncture. With our cutting-edge approach to pain management, I am confident in our ability to drive significant advancements in the field and enhance patient care where new, safer options are needed.”   Nancy Stagliano, Ph.D., chair of Latigo’s board of directors, said: “The addition of Nima represents a pivotal moment for Latigo. His extensive industry leadership and clinical development experience will propel us toward our goal of becoming a world leader in discovering and developing non-opioid pain medicines.”   Read the full announcement here: https://lnkd.in/gHJFupPx   #BioPharma #CaliforniaBiotech #LifeSciences #Biotech

As we celebrate the Fourth of July, we take a moment to reflect on the significance of the day when the United States laid down its foundation on the principles of freedom, democracy, and the pursuit of happiness. Wishing everyone a joyful and safe celebration! #IndependenceDay2024 #LatigoBio #Innovation #Healthcare #July4th

As we approach the middle of a momentous year, following the launch of Latigo Bio, we're taking a pause to reflect and recharge. In recognition of Independence Day and the efforts of our dedicated team, Latigo Bio will be closed for the week of July 4th. This break is our way of saying thank you to our team, providing everyone with the opportunity to spend quality time with family and friends, and to enjoy a well-deserved rest. #LatigoBio #July4th2024 #WorkLifeBalance #CompanyShutdown